These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9731068)

  • 1. Treatment of B-cell lymphoma with chimeric IgG and single-chain Fv antibody-interleukin-2 fusion proteins.
    Liu SJ; Sher YP; Ting CC; Liao KW; Yu CP; Tao MH
    Blood; 1998 Sep; 92(6):2103-12. PubMed ID: 9731068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity.
    Penichet ML; Harvill ET; Morrison SL
    J Interferon Cytokine Res; 1998 Aug; 18(8):597-607. PubMed ID: 9726441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
    Weiner GJ; Hillstrom JR
    J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
    Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
    Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and characterization of a single-gene encoded single-chain immunoglobulin-interleukin-2 fusion protein.
    Shu L; Qi CF; Hand PH; Schlom J; Kashmiri SV
    Immunotechnology; 1995 Dec; 1(3-4):231-41. PubMed ID: 9373351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties.
    Hornick JL; Khawli LA; Hu P; Lynch M; Anderson PM; Epstein AL
    Blood; 1997 Jun; 89(12):4437-47. PubMed ID: 9192768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2.
    Berinstein N; Starnes CO; Levy R
    J Immunol; 1988 Apr; 140(8):2839-45. PubMed ID: 3258621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand.
    Huang HI; Wu PY; Teo CY; Chen MN; Chen YC; Silin D; Tao MH
    Int J Cancer; 2004 Feb; 108(5):696-703. PubMed ID: 14696096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific IgG and IL-2 therapy of a syngeneic B-cell lymphoma in immunocompetent mice.
    Weiner GJ
    Int J Cancer Suppl; 1992; 7():63-6. PubMed ID: 1428408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice.
    Zheng XX; Steele AW; Hancock WW; Kawamoto K; Li XC; Nickerson PW; Li Y; Tian Y; Strom TB
    J Immunol; 1999 Oct; 163(7):4041-8. PubMed ID: 10491008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiotypic vaccine for treatment of human B-cell lymphoma. Construction of IgG variable regions from single malignant B cells.
    Terness P; Welschof M; Moldenhauer G; Jung M; Moroder L; Kirchhoff F; Kipriyanov S; Little M; Opelz G
    Hum Immunol; 1997; 56(1-2):17-27. PubMed ID: 9455490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.
    De Jonge J; Heirman C; de Veerman M; Van Meirvenne S; Moser M; Leo O; Thielemans K
    J Immunol; 1998 Aug; 161(3):1454-61. PubMed ID: 9686611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.
    Peng LS; Penichet ML; Morrison SL
    J Immunol; 1999 Jul; 163(1):250-8. PubMed ID: 10384123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma.
    Leung SO; Shevitz J; Pellegrini MC; Dion AS; Shih LB; Goldenberg DM; Hansen HJ
    Hybridoma; 1994 Dec; 13(6):469-76. PubMed ID: 7737671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system.
    Yang J; Kanter G; Voloshin A; Michel-Reydellet N; Velkeen H; Levy R; Swartz JR
    Biotechnol Bioeng; 2005 Mar; 89(5):503-11. PubMed ID: 15669088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
    Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K
    J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of BR96 binding sites for antigen and anti-idiotype by codon-based scanning mutagenesis.
    Rosok MJ; Eghtedarzadeh-Kondri M; Young K; Bajorath J; Glaser S; Yelton D
    J Immunol; 1998 Mar; 160(5):2353-9. PubMed ID: 9498776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
    Kwak LW; Young HA; Pennington RW; Weeks SD
    Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The experimental study on idiotypic DNA vaccine against human B-cell lymphoma to induce antitumor immune response].
    Zhong KL; Zhang WJ; Yuan Y; Wu Y; Zhang MW; Mao N
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):609-15. PubMed ID: 14706145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced susceptibility of recombinant polyclonal antibodies to inhibitory anti-variable domain antibody responses.
    Klitgaard JL; Coljee VW; Andersen PS; Rasmussen LK; Nielsen LS; Haurum JS; Bregenholt S
    J Immunol; 2006 Sep; 177(6):3782-90. PubMed ID: 16951339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.